Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAA06 in Relapsed/Refractory Neuroblastoma
NCT05562024Phase 1Recruiting
- Sponsor
- PersonGen BioTherapeutics
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAA06 in neuroblastoma, sponsored by PersonGen BioTherapeutics. Primary endpoints: Maximum Tolerated Dose at 3 years, Recommended Phase 2 Dose at 3 years and 1 more. Started Dec 2022; status: recruiting.
02
Drugs
TAA06
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT05562024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05562024.